-
公开(公告)号：US09174974B2
公开(公告)日：2015-11-03
申请号：US14405507
申请日：2013-06-05
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xiaojun Zhang , Peter Glunz , Eldon Scott Priestley , James A. Johnson , Nicholas Ronald Wurtz , Vladimir Ladziata
IPC: C07D401/12 , C07D401/14 , C07D413/12 , C07D273/02 , C07D413/14 , C07D417/14 , C07F9/6558
CPC classification number: C07D413/12 , C07D273/02 , C07D401/12 , C07D413/14 , C07D417/14 , C07F9/65583
Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.
Abstract translation: 本发明提供式（I）化合物：如说明书中所定义和包含任何这些新化合物的组合物。 这些化合物是可以用作药物的因子VIIa抑制剂。
-
公开(公告)号：US20250002497A1
公开(公告)日：2025-01-02
申请号：US18826736
申请日：2024-09-06
Applicant: Bristol-Myers Squibb Company , Université De Montréal
Inventor： Jacques Banville , Roger Rémillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/04 , C07B59/00 , C07D513/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R1, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US12084452B2
公开(公告)日：2024-09-10
申请号：US17902618
申请日：2022-09-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITÉ DE MONTRÉAL
Inventor： Jacques Banville , Roger Rémillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/04 , C07B59/00 , C07D513/04 , C07D519/00
CPC classification number: C07D487/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07D513/04 , C07D519/00 , C07B2200/05
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US11407733B2
公开(公告)日：2022-08-09
申请号：US16311835
申请日：2017-06-28
Applicant: Universite de Montreal , Bristol-Myers Squibb Company
Inventor： Eldon Scott Priestley , Samuel Kaye Reznik , Edward H. Ruediger , James R. Gillard , Oz Scott Halpern , Wen Jiang , Jeremy Richter , Rejean Ruel , Sasmita Tripathy , Wu Yang , Xiaojun Zhang
IPC: C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D409/14 , C07D417/14 , C07D491/107 , C07D401/10 , C07D235/26 , C07D413/10 , C07D471/04 , C07D257/04 , C07D405/14 , C07D233/90 , C07D498/10 , C07D413/14 , A61P9/04 , A61K31/41 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/4709 , A61K31/497 , A61K31/501 , C07D239/20 , C07D271/07
Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.
-
公开(公告)号：US10815224B2
公开(公告)日：2020-10-27
申请号：US16317232
申请日：2017-07-13
Applicant: Bristol-Myers Squibb Company
Inventor： Jeremy M. Richter , Xiaojun Zhang , Eldon Scott Priestley
IPC: C07D413/10 , C07D417/14 , C07D403/04 , C07D413/04 , C07D471/04 , C07D417/04 , A61P7/02 , C07D403/10 , C07D417/10
Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a monocyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
-
Patent Agency Ranking
公开(公告)号：US20190300520A1
公开(公告)日：2019-10-03
申请号：US16317218
申请日：2017-07-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Qinghong Fu , Xiaojun Zhang , Eldon Scott Priestley , Oz Scott Halpern , Samuel Kaye Reznik , Jeremy M. Richter
IPC: C07D417/14 , C07D513/04 , C07D417/10
Abstract: Disclosed are compounds of Formula (I) to (IV): [INSERT CHEMICAL STRUCTURE HERE] or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
-
公开(公告)号：US20190248771A1
公开(公告)日：2019-08-15
申请号：US16317232
申请日：2017-07-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jeremy M. Richter , Xiaojun Zhang , Eldon Scott Priestley
IPC: C07D413/10 , A61P7/02 , C07D403/10 , C07D417/10 , C07D417/14
Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), (V), (VI), (VII), or (VIII): (I) (II) (III) (IV) (V) (VI) (VII) (VIII) or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a monocyclic heteroaryl group substituted with zero to 3 R3a; and R1, R2, R3a, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
-
18.发明申请公开(公告)号：US20180305376A1
公开(公告)日：2018-10-25
申请号：US16020043
申请日：2018-06-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITE DE MONTREAL
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , A61K31/5377 , A61K31/435 , C07D487/04 , A61K31/541 , A61K31/553 , A61K31/433 , A61K31/496 , A61K31/497 , A61K31/454 , A61K45/06 , A61K31/4439 , A61K31/5025 , C07B59/00 , A61K31/55 , A61K51/04 , A61K31/5386 , C07D519/00
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
19.发明申请IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION 有权作为用于治疗细胞聚集的蛋白激活受体4（PAR4）抑制剂的咪唑并噻唑和咪唑并吡啶衍生物公开(公告)号：US20150094297A1
公开(公告)日：2015-04-02
申请号：US14396771
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： Jacques Banville , Roger Rèmillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , A61K31/541 , A61K31/5377 , A61K31/5025 , C07D487/04 , A61K31/497 , A61K31/454 , A61K31/4439 , A61K31/433 , A61K31/553 , A61K31/496
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
Abstract translation: 本发明提供式I的噻唑化合物，其中W，Y，R0，R2，R4，R5，R6，R7，X1，X2，X3和X4如本文所定义，或立体异构体，互变异构体，药学上可接受的盐， 或其溶剂合物形式，其中所有变量如本文所定义。 这些化合物是血小板聚集的抑制剂，因此可以用作治疗或预防血栓栓塞障碍的药物。
-
20.发明授权公开(公告)号：US11932658B2
公开(公告)日：2024-03-19
申请号：US17142288
申请日：2021-01-06
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Xiaojun Zhang , Eldon Scott Priestley , Oz Scott Halpern , Wen Jiang , Samuel Kaye Reznik , Jeremy M. Richter
IPC: C07D491/04 , A61K31/498 , A61P7/02 , C07D493/04 , C07D495/04 , C07D498/04 , C07D513/04 , C07D515/14 , C07D519/00
CPC classification number: C07D519/00 , A61P7/02 , C07D515/14
Abstract: Disclosed are compounds of Formula (I) to (VIII):
or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and Ri, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.048 seconds)
